Sirolimus Is Associated With Veno-Occlusive Disease of the Liver After Myeloablative Allogeneic Stem Cell Transplantation

Publication Type
Journal Article
Year of Publication
2008
Authors
Cutler, C; Stevenson, K; Kim, HT; Richardson, P; Ho, VT; Linden, E; Revta, C; Ebert, R; Warren, D; Choi, S; Koreth, J; Armand, P; Alyea, E; Carter, S; Horowitz, M; Antin, JH; Soiffer, R
Secondary
Blood
Volume
112
Start Page
4425
Pagination
4425-4431
Date Published
12/2008
Keywords
Drug Combinations; Female; Graft vs Host Disease/prevention & control; Hematopoietic Stem Cell Transplantation*/methods; Hepatic Veno-Occlusive Disease/chemically induced*; Hepatic Veno-Occlusive Disease/epidemiology; Humans; Immunosuppressive Agents
Abstract
{Sirolimus is an effective agent used in graft-versus-host disease (GVHD) prophylaxis after allogeneic transplantation. It also has antiproliferative effects on vascular endothelium when used to coat coronary artery stents. We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrospectively reviewed the records of 488 patients to determine the association between sirolimus and VOD. When used with cyclophosphamide/total body irradiation (Cy/TBI) conditioning, sirolimus is associated with an increased incidence of VOD (OR 2.35
URL
http://www.ncbi.nlm.nih.gov/pubmed/18776081